TABLE 2.
Gene producta | Disease association | Reference(s) |
---|---|---|
TLRs | ||
TLR2 | Susceptibility to leprosy and tuberculosis | 33, 167 |
TLR2 | Protection from Lyme disease; susceptibility to staphylococcal disease and tuberculosis | 217, 278, 326 |
TLR2 | Increased severity of genital herpes | 37 |
TLR3 | Susceptibility to HSV encephalitis | 400 |
TLR4 | Susceptibility to infection with gram-negative bacteria, malaria, and RSV | 4, 218, 255, 360 |
TLR4 | Susceptibility to meningococcal sepsis | 337 |
TLR4 | Protection from Legionnaires' disease | 116 |
TLR5 | Susceptibility to Legionnaires' disease | 117 |
TLR7 | Protection from hepatic fibrosis in chronic HCV infection | 325 |
TLR9 | Susceptibility to SLE | 361 |
TLR9 | Rapid progression of HIV infection | 36 |
TLR9 | Increased risk of low birth wt in malaria during pregnancy | 256 |
Signaling proteins | ||
MyD88 | Susceptibility to infection with pyogenic bacteria | 376 |
Mal | Protection from invasive pneumococcal disease, malaria, and tuberculosis | 185 |
IRAK1 | Increased severity of sepsis | 20 |
IRAK4 | Susceptibility to infection with pyogenic bacteria | 294 |
NEMO | EDA-ID; susceptibility to infection with pyogenic bacteria, mycobacteria, herpesviruses, fungi | 78, 195, 282 |
IκBα | EDA-ID | 62 |
IRF5 | Increased risk of SLE | 105, 183 |
NLRs | ||
NOD2 | Susceptibility to Crohn's disease | 144, 277 |
NOD2 | Blau syndrome, early-onset sarcoidosis | 166 |
NOD2 | Susceptibility to psoriatic arthritis | 299 |
NALP1 | Susceptibility to vitiligo-associated multiple autoimmune diseases | 160 |
NALP3 | Periodic fever syndromes | 86 |
Miscellaneous | ||
CD14 | Susceptibility to RSV bronchiolitis | 147 |
UNC93B | Susceptibility to HSV encephalitis | 52 |
In cases where the same PRR gene product is listed repeatedly, each entry represents a different mutation/SNP.